q&a: difference between biochemical relapse and clinical relapse? - blood cancer onctalk 2023
Published 4 months ago • 15 plays • Length 3:23Download video MP4
Download video MP3
Similar videos
-
4:10
what is smoldering multiple myeloma? - blood cancer onctalk 2023
-
3:53
identifying smoldering multiple myeloma patients: risk factors - blood cancer onctalk 2023
-
3:56
bispecific antibodies in myeloma: approvals and clinical trials - blood cancer onctalk 2023
-
3:13
q&a: is multiple myeloma a myelogenous cancer? - blood cancer onctalk 2023
-
1:56
types of bispecific antibodies - blood cancer onctalk 2023
-
3:32
q&a: difference between autologous vs. allogeneic transplant in myeloma? - blood cancer onctalk 2023
-
1:37
pros and cons of bispecific antibodies - blood cancer onctalk 2023
-
4:20
the spectrum of disease in multiple myeloma - blood cancer onctalk
-
3:36
q&a: financial or location limitations to bispecific antibody treatments? -blood cancer onctalk 2023
-
4:20
bispecific treatments for multiple myeloma - blood cancers video library
-
4:11
molecular testing: liquid vs. tissue, and insurance coverage - lung cancer onctalk 2022
-
4:16
cancer genetics 101: standard vs liquid biopsy - program: patient education ambassadors 2023-24
-
2:14
q&a: what are costs and side effects of antibody drug conjugates? - onctalk lung 2023
-
4:55
the importance of biomarker testing: what is liquid biopsy?
-
4:35
the importance of biomarker testing: what is liquid biopsy? - targeted therapies in lung cancer 2023
-
8:06
advances in multiple myeloma: what is needed to get to a cure? - blood cancer onctalk
-
4:11
bispecific antibodies in myeloma: approvals and clinical trials
-
4:52
biochemistry students talk about their research: gene regulation in breast cancer with sarah mackie
-
1:49
q&a: when should a patient do biomarker retesting? - targeted therapies in lung cancer 2023